Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation
- 16 June 2023
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (6) , 1062-1069
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Canada
- Ministério da Ciência, Tecnologia e Inovação (3–17632)
- ISF (2039/20)
- Genome Canada
This publication has 20 references indexed in Scilit:
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Physiological and pharmacological characterization of the N1303K mutant CFTRJournal of Cystic Fibrosis, 2018
- A multiple reader scoring system for Nasal Potential Difference parametersJournal of Cystic Fibrosis, 2017
- Atomic Structure of the Cystic Fibrosis Transmembrane Conductance RegulatorCell, 2016
- From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutationsMolecular Biology of the Cell, 2016
- Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet Respiratory Medicine, 2014
- A functional CFTR assay using primary cystic fibrosis intestinal organoidsNature Medicine, 2013
- NIH Image to ImageJ: 25 years of image analysisNature Methods, 2012
- Nasal potential difference measurements in patients with atypical cystic fibrosisEuropean Respiratory Journal, 2001
- Evidence that Systemic Gentamicin Suppresses Premature Stop Mutations in Patients with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2001